A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: Enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities

Francisco Bracho, Mark D. Krailo, Violet Shen, Sharon Bergeron, Virginia Davenport, Wen Liu-Mares, Bruce R. Blazar, Angela Panoskaltsis-Mortari, Carmella Van De Ven, Rita Secola, Matthew M. Ames, Joel M. Reid, Gregory H. Reaman, Mitchell S. Cairo

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: Enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities'. Together they form a unique fingerprint.

Medicine & Life Sciences